.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA58_EfgartigimodAlfa.EfgartigimodAlfa .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA58_EfgartigimodAlfa.EfgartigimodAlfa| name: | EfgartigimodAlfa |
| ATC code: | L04AA58 | route: | intravenous |
| n-compartments | 2 |
Efgartigimod alfa is a human IgG1-derived Fc fragment designed to bind to the neonatal Fc receptor (FcRn), resulting in a reduction of circulating IgG levels. It is approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive.
Pharmacokinetic parameters as reported in healthy adult subjects after intravenous infusion.
Jing, S, et al., & Pu, X (2024). Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants. Drugs in R&D 24(4) 505–515. DOI:10.1007/s40268-024-00490-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39368043